KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Q3 2025 value amounting to $21.6 million.

  • Acadia Pharmaceuticals' Cost of Revenue rose 1479.56% to $21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.6 million, marking a year-over-year increase of 852.96%. This contributed to the annual value of $81.8 million for FY2024, which is 9655.36% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Cost of Revenue is $21.6 million, which was up 1479.56% from $20.7 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Cost of Revenue ranged from a high of $23.0 million in Q1 2024 and a low of $1.7 million during Q1 2023
  • Over the past 5 years, Acadia Pharmaceuticals' median Cost of Revenue value was $10.7 million (recorded in 2021), while the average stood at $11.3 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Cost of Revenue tumbled by 7753.68% in 2022 and then soared by 127678.46% in 2024.
  • Acadia Pharmaceuticals' Cost of Revenue (Quarter) stood at $10.7 million in 2021, then tumbled by 77.54% to $2.4 million in 2022, then soared by 641.44% to $17.9 million in 2023, then increased by 21.87% to $21.8 million in 2024, then decreased by 0.72% to $21.6 million in 2025.
  • Its Cost of Revenue stands at $21.6 million for Q3 2025, versus $20.7 million for Q2 2025 and $20.4 million for Q1 2025.